Company news

Telix Pharmaceuticals Limited news in 2026

Telix Pharmaceuticals Limited's news releases, calls and decks from 2026, newest first.

View company

First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer

July 15, 2026

Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing

July 15, 2026

Notification of cessation of securities - TLX

July 10, 2026

FDA Alignment to Advance ProstACT Global Phase 3 Trial

July 1, 2026

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

June 22, 2026

ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026

June 1, 2026

Telix and United Imaging Announce Strategic Theranostics Collaboration

June 2, 2026

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

May 18, 2026

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches

May 15, 2026

New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC

May 4, 2026

TLX101-Px (Pixlumi®) MAA Accepted in Europe

April 30, 2026

OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

April 29, 2026

Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach

April 27, 2026

ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026

April 21, 2026

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

April 14, 2026

Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds

April 14, 2026

Telix Successfully Prices Upsized US$600M Convertible Bonds

April 14, 2026

Telix Investor Presentation April 2026

April 14, 2026

Telix Refinances Convertible Bonds

April 14, 2026

Telix and Regeneron Announce Strategic Radiopharma Collaboration

April 13, 2026

Regeneron and Telix Announce Strategic Radiopharma Collaboration

April 13, 2026

Telix and Regeneron Announce Radiopharma Collaboration

April 12, 2026

FDA Accepts NDA for TLX101-Px (Pixclara)

April 9, 2026

Telix Strengthens Board with Additional Director Appointments

April 8, 2026

Q1 2026 Strong Revenue Growth and Tx Pipeline Advancement

April 6, 2026

Telix Appoints David Gill as Non-Executive Director

April 1, 2026

Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.

March 20, 2026

Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate

March 15, 2026

Telix Resubmits NDA to FDA for Pixclara Brain Cancer Imaging

March 15, 2026

ProstACT Global Phase 3 (Part 1) Results Presentation

March 9, 2026

ProstACT Global Phase 3 (Part 1) Achieves Primary Objectives

March 9, 2026

Investor Education Webinar

March 1, 2026

Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging

February 27, 2026

Telix to Participate in Oppenheimer and TD Cowen Conferences

February 20, 2026

FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

February 19, 2026

2025 Full Year Results Presentation

February 19, 2026

Appendix 4E and 2025 Annual Report

February 19, 2026

2025 Full Year Results Announcement

February 19, 2026

Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging

February 17, 2026

Telix Submits EU MAA for TLX101-Px Brain Cancer Imaging

February 17, 2026

Telix Full Year Results 2025 Investor Webcast Notification

February 3, 2026

First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients

January 28, 2026

Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging

January 19, 2026

Telix Achieves FY25 Guidance - US$804M, Q4 Growth

January 20, 2026

Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

January 20, 2026

Chinese NMPA Accepts New Drug Application for Illuccix

January 19, 2026

First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

January 16, 2026

Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference

January 8, 2026

← Newer news releases

Calls in 2026

Decks in 2026